UK Markets closed

Green Cross Corporation (006280.KS)

KSE - KSE Delayed price. Currency in KRW
Add to watchlist
269,500.00+2,000.00 (+0.75%)
At close: 3:30PM KST
Full screen
Previous close267,500.00
Bid264,000.00 x 0
Ask264,500.00 x 0
Day's range267,500.00 - 279,500.00
52-week range249,500.00 - 538,000.00
Avg. volume132,413
Market cap3.076T
Beta (5Y monthly)0.95
PE ratio (TTM)N/A
Earnings date01 Nov 2021 - 05 Nov 2021
Forward dividend & yield1,500.00 (0.47%)
Ex-dividend date29 Dec 2020
1y target estN/A
  • Business Wire

    GC Pharma Announces GreenGene F Approval in China for the Treatment of Haemophilia A

    YONGIN, South Korea, August 12, 2021--GC Pharma (006280.KS) today announced the approval of GreenGene F (Beroctocog alfa) [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis of bleeding episodes in individuals with haemophilia A in China by the National Medical Products Administration (NMPA). GreenGene F was initially approved by the Korean health authority in 2010 for control and prevention of bleeding episodes in patients with haemophilia A.

  • Business Wire

    GC Pharma Announces Publication of Results From Phase III Clinical Trial of ‘GC5107’ Immune Globulin in Frontiers in Immunology

    YONGIN, South Korea, August 11, 2021--GC Pharma (006280.KS) today announced that Frontiers in Immunology has published the safety and final efficacy results from the pivotal Phase III clinical trial of GC5107, its 10% Immune Globulin product for intravenous administration.

  • Business Wire

    GC Pharma Reports Q2 2021 Results

    YONGIN, South Korea, August 02, 2021--GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 30 June 2021.